Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 20
1992 27
1993 47
1994 72
1995 78
1996 105
1997 108
1998 137
1999 122
2000 164
2001 149
2002 116
2003 110
2004 141
2005 155
2006 137
2007 131
2008 130
2009 141
2010 128
2011 113
2012 115
2013 107
2014 95
2015 116
2016 86
2017 107
2018 126
2019 76
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

2,916 results
Results by year
Filters applied: . Clear all
Page 1
NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E, Scaltriti M, Drilon A. Cocco E, et al. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747. doi: 10.1038/s41571-018-0113-0. Nat Rev Clin Oncol. 2018. PMID: 30333516 Free PMC article. Review.
Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F, Rudzinski ER, Sepulveda AR. Penault-Llorca F, et al. J Clin Pathol. 2019 Jul;72(7):460-467. doi: 10.1136/jclinpath-2018-205679. Epub 2019 May 9. J Clin Pathol. 2019. PMID: 31072837 Free PMC article. Review.
Optical Activation of TrkA Signaling.
Duan L, Hope JM, Guo S, Ong Q, Fran├žois A, Kaplan L, Scherrer G, Cui B. Duan L, et al. ACS Synth Biol. 2018 Jul 20;7(7):1685-1693. doi: 10.1021/acssynbio.8b00126. Epub 2018 Jul 12. ACS Synth Biol. 2018. PMID: 29975841
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, De Braud FG. Drilon A, et al. Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9. Cancer Discov. 2017. PMID: 28183697 Free PMC article. Clinical Trial.
Targeting TRK family proteins in cancer.
Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Khotskaya YB, et al. Pharmacol Ther. 2017 May;173:58-66. doi: 10.1016/j.pharmthera.2017.02.006. Epub 2017 Feb 4. Pharmacol Ther. 2017. PMID: 28174090 Review.
NGF/TrkA Signaling as a Therapeutic Target for Pain.
Hirose M, Kuroda Y, Murata E. Hirose M, et al. Pain Pract. 2016 Feb;16(2):175-82. doi: 10.1111/papr.12342. Epub 2015 Aug 27. Pain Pract. 2016. PMID: 26452158 Review.
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
Chiang S, Cotzia P, Hyman DM, Drilon A, Tap WD, Zhang L, Hechtman JF, Frosina D, Jungbluth AA, Murali R, Park KJ, Soslow RA, Oliva E, Iafrate AJ, Benayed R, Ladanyi M, Antonescu CR. Chiang S, et al. Am J Surg Pathol. 2018 Jun;42(6):791-798. doi: 10.1097/PAS.0000000000001055. Am J Surg Pathol. 2018. PMID: 29553955 Free PMC article.
2,916 results
Jump to page
Feedback